The role of chromatin, microRNAs, and tumor stem cells in ovarian cancer

Cancer Biomarkers

Volumn 8, Issue 4-5, 2010, Pages 203-221

  Balch, Curtis ^a,b   Nephew, Kenneth P ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; AZACITIDINE; BELINOSTAT; BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; CARBOPLATIN; DNA; DNA METHYLTRANSFERASE INHIBITOR; DOXORUBICIN; HISTONE DEACETYLASE INHIBITOR; HYDRALAZINE; MICRORNA; PLATINUM DERIVATIVE; ROMIDEPSIN; TOPOTECAN; TUMOR MARKER; VALPROIC ACID; VORINOSTAT;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER STEM CELL; CHROMATIN; CUTANEOUS T CELL LYMPHOMA; DNA METHYLATION; DNA SEQUENCE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; EARLY DIAGNOSIS; EPIGENETICS; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HUMAN; LOW DRUG DOSE; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; NONHUMAN; ONCOGENE; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

ANIMALS; CHROMATIN; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 81155132143     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2011-0214     Document Type: Article

References (205)

1. American Cancer Society, Atlanta, GA: What are the key statistics about ovarian cancer? http://www.cancer.org/ cancer/ovariancancer/detailedguide/ ovarian-cancer-key-stati stics, 2010.
2. R.F. Ozols, Systemic therapy for ovarian cancer: current status and newtreatments, SeminOncol 33(2 Suppl 6) (2006), S3-S11.
3. T.J. Herzog and B. Pothuri, Ovarian cancer: a focus on management of recurrent disease, Nat Clin Pract Oncol 3(11) (2006), 604-611. (Pubitemid 44669715)
4. I. Cass, R.L. Baldwin, T. Varkey, R. Moslehi, S.A. Narod and B.Y. Karlan, Improved survival in women with BRCAassociated ovarian carcinoma, Cancer 97(9) (2003), 2187-2195. (Pubitemid 36444059)
5. D.S. Tan, C. Rothermundt, K. Thomas, E. Bancroft, R. Eeles, S. Shanley, A. Ardern-Jones, A. Norman, S.B.Kaye and M.E. Gore, BRCAness syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations, J Clin Oncol 26(34) (2008), 5530-5536.
6. J.W. Chiang, B.Y. Karlan, L. Cass and R.L. Baldwin, BRCA1 promoter methylation predicts adverse ovarian cancer prognosis, Gynecologic Oncology 101(3) (2006), 403-410. (Pubitemid 43729975)
7. C.N. Landen, Jr., M.J. Birrer and A.K. Sood, Early events in the pathogenesis of epithelial ovarian cancer, J Clin Oncol 26(6) (2008), 995-1005. (Pubitemid 351398093)
8. R.G.Moore, S. MacLaughlan, R.C. Bast, Jr., Current state of biomarker development for clinical application in epithelial ovarian cancer, Gynecol Oncol 116(2) (2010), 240-245.
9. R.C. Bast, Jr., CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease, Cancer 116(12) (2010), 2850-2853.
10. D.L. Clarke-Pearson, Clinical practice. Screening for ovarian cancer, N Engl J Med 361(2) (2009), 170-177.
11. V. Kulasingam, M.P. Pavlou and E.P. Diamandis, Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer, Nat Rev Cancer 10(5) (2010), 371-378.
12. E.T. Fung, A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance, Clin Chem 56(2) (2010), 327-329.
13. K.M. Hatle, W. Neveu, O. Dienz, S. Rymarchyk, R. Barrantes, S. Hale, N. Farley, K.M. Lounsbury, J.P. Bond, D. Taatjes and M. Rincon, Methylation-controlled J protein promotes c-Jun degradation to prevent ABCB1 transporter expression, Mol Cell Biol 27(8) (2007), 2952-2966. (Pubitemid 46581309)
14. US Food and Drug Administration, FDA clears a test for ovarian cancer: test can help identify potential malignancies, guide surgical decisions, http://www.fda.gov/News Events/Newsroom/PressAnnouncements/ucm182057.htm, 2009.
15. T. Edgell, G. Martin-Roussety, G. Barker, D.J. Autelitano, D. Allen, P. Grant and G.E. Rice, Phase II biomarker trial of a multimarker diagnostic for ovarian cancer, J Cancer Res Clin Oncol 136(7) (2010), 1079-1088.
16. B. Nolen, L. Velikokhatnaya, A. Marrangoni, K. De Geest, A. Lomakin, R.C. Bast, Jr. and A. Lokshin, Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass, Gynecologic Oncology 117(3) (2010), 440-445.
17. Z. Yurkovetsky, S. Skates, A. Lomakin, B. Nolen, T. Pulsipher, F. Modugno, J. Marks, A. Godwin, E. Gorelik, I. Jacobs, U. Menon, K. Lu, D. Badgwell, R.C. Bast, Jr. and A.E. Lokshin, Development of a multimarker assay for early detection of ovarian cancer, J Clin Oncol 28(13) (2010), 2159-2166.
18. P.S. Kim, S. Djazayeri and R. Zeineldin, Novel nanotechnology approaches to diagnosis and therapy of ovarian cancer, Gynecologic Oncology 120(3) (2011), 393-403.
19. A.M. Gonzalez-Angulo, B.T. Hennessy and G.B. Mills, Future of personalized medicine in oncology: a systems biology approach, J Clin Oncol 28(16) (2010), 2777-2783.
20. K. Levanon, C. Crum and R. Drapkin, New insights into the pathogenesis of serous ovarian cancer and its clinical impact, J Clin Oncol 26(32) (2008), 5284-5293.
21. A.A. Tone, M. Letarte and T.J. Brown, Emerging concepts in epithelial ovarian cancer: highlights of the 4th Canadian conference on ovarian cancer research, Eur J GynaecolOncol 30(6) (2009), 625-630.
22. R.S. Tuma, Origin of ovarian cancer may have implications for screening, J Natl Cancer Inst 102(1) (2010), 11-13.
23. A.K. Folkins, E.A. Jarboe, M.H. Roh and C.P. Crum, Precursors to pelvic serous carcinoma and their clinical implications, Gynecologic Oncology 113(3) (2009), 391-396.
24. K. Levanon, V. Ng, H.Y. Piao, Y. Zhang, M.C. Chang, M.H. Roh, D.W. Kindelberger, M.S. Hirsch, C.P. Crum, J.A. Marto and R. Drapkin, Primary ex vivo cultures of human fallopian tube epithelium as amodel for serous ovarian carcinogenesis, Oncogene 29(8) (2010), 1103-1113.
25. I. Miyoshi, K. Takahashi, Y. Kon, T. Okamura, Y. Mototani, Y. Araki and N. Kasai, Mouse transgenic for murine oviductspecific glycoprotei promoter-driven simian virus 40 large T-antigen: tumor formation and its hormonal regulation, Mol Reprod Dev 63(2) (2002), 168-176. (Pubitemid 34971376)
26. B.B. Zhou, H. Zhang, M. Damelin, K.G. Geles, J.C. Grindley and P.B. Dirks, Tumour-initiating cells: challenges and opportunities for anticancer drug discovery, Nat Rev Drug Discov 8(10) (2009), 806-823.
27. M. Dean, T. Fojo and S. Bates, Tumour stem cells and drug resistance, Nat Rev Cancer 5(4) (2005), 275-284. (Pubitemid 40488633)
28. S. Zhang, C. Balch, M.W. Chan, H.C. Lai, D. Matei, J.M. Schilder, P.S. Yan, T.H. Huang and K.P. Nephew, Identification and characterization of ovarian cancer-initiating cells from primary human tumors, Cancer Research 68(11) (2008), 4311-4320.
29. N. Ahmed, K. Abubaker, J. Findlay andM. Quinn, Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer, Curr Cancer Drug Targets 10(3) (2010), 268-278.
30. M.D. Curley, V.A. Therrien, C.L. Cummings, P.A. Sergent, C.R. Koulouris, A.M. Friel, D.J. Roberts, M.V. Seiden, D.T. Scadden, B.R. Rueda and R. Foster, CD133 Expression Defines a Tumor Initiating Cell Population in Primary Human Ovarian Cancer, Stem Cells 27(12) (2009), 2875-2883.
31. N.K. Kurrey, S.P. Jalgaonkar, A.V. Joglekar, A.D. Ghanate, P.D. Chaskar, R.Y. Doiphode and S.A. Bapat, Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells, Stem Cells 27(9) (2009), 2059-2068.
32. C.N. Landen, Jr., B. Goodman, A.A. Katre, A.D. Steg, A.M. Nick, R.L. Stone, L.D. Miller, P.V. Mejia, N.B. Jennings, D.M. Gershenson, R.C. Bast, Jr., R.L. Coleman, G. Lopez- Berestein and A.K. Sood, Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer, Molecular Cancer Therapeutics 9(12) (2010), 3186-3199.
33. S. Peng, N.J. Maihle and Y. Huang, Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer, Oncogene 29(14) (2010), 2153-2159.
34. S. Rizzo, J.M. Hersey, P.Mellor, W. Dai, A. Santos-Silva, D. Liber, L. Luk, I. Titley, C.P. Carden, G. Box, D.L. Hudson, S.B. Kaye and R. Brown, Ovarian Cancer Stem Cell-Like Side Populations Are Enriched Following Chemotherapy and Overexpress EZH2, Mol Cancer Ther 10(2) (2011), 325-335.
35. R. Strauss, Z.Y. Li, Y. Liu, I. Beyer, J. Persson, P. Sova, T. Moller, S. Pesonen, A. Hemminki, P. Hamerlik, C. Drescher, N. Urban, J. Bartek and A. Lieber, Analysis of epithelial andmesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity, PloS One 6(1) (2011), e16186.
36. P.P. Szotek, R. Pieretti-Vanmarcke, P.T.Masiakos, D.M.Dinulescu, D. Connolly, R. Foster, D. Dombkowski, F. Preffer, D.T. Maclaughlin and P.K. Donahoe, Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness, Proc Natl Acad Sci USA 103(30) (2006), 11154-11159. (Pubitemid 44156488)
37. A.B. Alvero, R. Chen, H.H. Fu,M.Montagna, P.E. Schwartz, T. Rutherford, D.A. Silasi, K.D. Steffensen, M. Waldstrom, I. Visintin and G. Mor, Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance, Cell Cycle 8(1) (2009), 158-166.
38. M.F. Shi, J. Jiao, W.G. Lu, F. Ye, D. Ma, Q.G. Dong and X. Xie, Identification of cancer stem cell-like cells from human epithelial ovarian carcinoma cell line, Cell Mol Life Sci 67(22) (2010), 3915-3925.
39. T. Baba, P.A. Convery, N. Matsumura, R.S. Whitaker, E. Kondoh, T. Perry, Z. Huang, R.C. Bentley, S. Mori, S. Fujii, J.R. Marks, A. Berchuck and S.K. Murphy, Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells, Oncogene 28(2) (2009), 209-218.
40. N. Dahiya, C.A. Sherman-Baust, T.L. Wang, B. Davidson, M. Shih Ie, Y. Zhang, W. Wood, 3rd, K.G. Becker and P.J.Morin, MicroRNA expression and identification of putative miRNA targets in ovarian cancer, PloS One 3(6) (2008), e2436.
41. X. Wei, D. Dombkowski, K. Meirelles, R. Pieretti- Vanmarcke, P.P. Szotek, H.L. Chang, F.I. Preffer, P.R. Mueller, J. Teixeira, D.T. MacLaughlin and P.K. Donahoe, Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics, Proc Natl Acad Sci USA 107(44) (2010), 18874-18879.
42. A.P. Kusumbe, A.M. Mali and S.A. Bapat, CD133- expressing stem cells associated with ovarian metastases establish an endothelial hierarchy and contribute to tumor vasculature, Stem Cells 27(3) (2009), 498-508.
43. Y. Kobayashi, K.I. Seino, S. Hosonuma, T. Ohara, H. Itamochi, S. Isonishi, T. Kita, H.Wada, S. Kojo and K. Kiguchi, Side population is increased in paclitaxel-resistant ovarian cancer cell lines regardless of resistance to cisplatin, Gynecologic Oncology (2011).
44. M.A. Goodell, K. Brose, G. Paradis, A.S. Conner and R.C. Mulligan, Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo, J Exp Med 183(4) (1996), 1797-1806. (Pubitemid 26134320)
45. C. Ginestier, M.H. Hur, E. Charafe-Jauffret, F. Monville, J. Dutcher, M. Brown, J. Jacquemier, P. Viens, C.G. Kleer, S. Liu, A. Schott, D. Hayes, D. Birnbaum, M.S. Wicha and G. Dontu, ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome, Cell Stem Cell 1(5) (2007), 555-567. (Pubitemid 350056407)
46. S. Corti, F. Locatelli, D. Papadimitriou, C. Donadoni, S.Salani, R. Del Bo, S. Strazzer, N. Bresolin and G.P. Comi, Identification of a primitive brain-derived neural stem cell population based on aldehyde dehydrogenase activity, Stem Cells 24(4) (2006), 975-985. (Pubitemid 44464730)
47. S. Deng, X. Yang, H. Lassus, S. Liang, S. Kaur, Q. Ye, C. Li, L.P. Wang, K.F. Roby, S. Orsulic, D.C. Connolly, Y. Zhang, K. Montone, R. Butzow, G. Coukos and L. Zhang, Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers, PloS One 5(4) (2010), e10277.
48. K. Le Moguen, H. Lincet, E. Deslandes, M. Hubert-Roux, C. Lange, L. Poulain, P. Gauduchon and B. Baudin, Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1- R10, Proteomics 6(19) (2006), 5183-5192. (Pubitemid 44549991)
49. I.H. Park, R. Zhao, J.A. West, A. Yabuuchi, H. Huo, T.A. Ince, P.H. Lerou, M.W. Lensch and G.Q. Daley, Reprogramming of human somatic cells to pluripotency with defined factors, Nature 451(7175) (2008), 141-146.]
50. M. Ramalho-Santos, iPS cells: insights into basic biology, Cell 138(4) (2009), 616-618.
51. X. Yang, X. Lin, X. Zhong, S. Kaur, N. Li, S. Liang, H. Lassus, L. Wang, D. Katsaros, K. Montone, X. Zhao, Y. Zhang, R. Butzow, G. Coukos and L. Zhang, Double-negative feedback loop between reprogramming factorLIN28 andmicroRNAlet- 7 regulates aldehyde dehydrogenase 1-positive cancer stem cells, Cancer Research 70(22) (2010), 9463-9472.
52. E.M. Hurt, J.N. Saykally, B.M. Anose, K.R. Kalli and M.M. Sanders, Expression of the ZEB1 (deltaEF1) transcription factor in human: additional insights, Mol Cell Biochem 318(1-2) (2008), 89-99.
53. J.M. Lee, S. Dedhar, R. Kalluri and E.W. Thompson, The epithelial-mesenchymal transition: new insights in signaling, development, and disease, J Cell Biol 172(7) (2006), 973-981.
54. P.A. Jones and S.B. Baylin, The epigenomics of cancer, Cell 128(4) (2007), 683-692. (Pubitemid 46273572)
55. M. Esteller, Epigenetics in cancer, N Engl J Med 358(11) (2008), 1148-1159.
56. M. Widschwendter, G. Jiang, C. Woods, H.M. Muller, H. Fiegl, G. Goebel, C.Marth, E.Muller-Holzner, A.G. Zeimet, P.W. Laird and M. Ehrlich, DNA hypomethylation and ovarian cancer biology, Cancer Research 64 (13) (2004), 4472-4480. (Pubitemid 38856918)
57. J. Pattamadilok, N. Huapai, P. Rattanatanyong, A. Vasurattana, S. Triratanachat, D. Tresukosol and A. Mutirangura, LINE-1 hypomethylation level as a potential prognostic factor for epithelial ovarian cancer, International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society 18(4) (2008), 711-717. (Pubitemid 352020191)
58. M. Esteller, J.M. Silva, G. Dominguez, F. Bonilla, X.Matias- Guiu, E. Lerma, E. Bussaglia, J. Prat, I.C. Harkes, E.A. Repasky, E. Gabrielson, M. Schutte, S.B. Baylin and J.G. Herman, Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors, J Natl Cancer Inst 92(7) (2000), 564-569. (Pubitemid 30212318)
59. A. Catteau, W.H. Harris, C.F. Xu and E. Solomon, Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics, Oncogene 18(11) (1999), 1957-1965. (Pubitemid 29150082)
60. C. Balch, F. Fang, D.E. Matei, T.H. Huang and K.P. Nephew, Minireview: epigenetic changes in ovarian cancer, Endocrinology 150(9) (2009), 4003-4011.
61. C.A. Barton, S.J. Clark, N.F. Hacker and P.M. O'Brien, Epigenetic markers of ovarian cancer, Adv Exp Med Biol 622 (2008), 35-51.
62. K. Kurose, X.P. Zhou, T. Araki, S.A. Cannistra, E.R. Maher and C. Eng, Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas, Am J Pathol 158(6) (2001), 2097-2106. (Pubitemid 32545195)
63. H. Fiegl, G.Windbichler, E. Mueller-Holzner, G. Goebel, M. Lechner, I.J. Jacobs and M. Widschwendter, HOXA11 DNAmethylation-a novel prognostic biomarker in ovarian cancer, International Journal of Cancer Journal International du Cancer 123(3) (2008), 725-729. (Pubitemid 351898435)
64. M. Widschwendter, S. Apostolidou, A.A. Jones, E.O. Fourkala, R. Arora, C.L. Pearce, M.A. Frasco, A. Ayhan, M. Zikan, D. Cibula, C.A. Iyibozkurt, E. Yavuz, C. Hauser- Kronberger, L. Dubeau, U. Menon and I.J. Jacobs, HOXA methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer: a proof of principle study, International Journal of Cancer Journal International du Cancer 125(9) (2009), 2214-2218.
65. S.A. Bapat, A.M. Mali, C.B.Koppikar and N.K.Kurrey, Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Research 65(8) (2005), 3025-3029. (Pubitemid 40524578)
66. M.V. Barbolina, B.P. Adley, D.L. Kelly, J. Shepard, A.J. Fought, D. Scholtens, P. Penzes, L.D. Shea and M.S. Stack, Downregulation of connective tissue growth factor by threedimensional matrix enhances ovarian carcinoma cell invasion, International Journal of Cancer Journal International du Cancer 125(4) (2009), 816-825.
67. C.A. Barton, N.F. Hacker, S.J. Clark and P.M.O'Brien, DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment, Gynecologic Oncology 109(1) (2008), 129-139.
68. R. Kikuchi, H. Tsuda, Y. Kanai, T. Kasamatsu, K. Sengoku, S. Hirohashi, J. Inazawa and I. Imoto, Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer, Cancer Research 67(15) (2007), 7095-7105. (Pubitemid 47206536)
69. K. Sawada, A.K.Mitra, A.R. Radjabi, V. Bhaskar, E.O. Kistner, M. Tretiakova, S. Jagadeeswaran, A. Montag, A. Becker, H.A. Kenny, M.E. Peter, V. Ramakrishnan, S.D. Yamada and E. Lengyel, Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target, Cancer Research 68(7) (2008), 2329-2339. (Pubitemid 351521807)
70. A. Wiley, D. Katsaros, H. Chen, I.A. Rigault de la Longrais, A. Beeghly, M. Puopolo, R. Singal, Y. Zhang, A. Amoako, D. Zelterman and H. Yu, Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential, Cancer 107(2) (2006), 299-308. (Pubitemid 44036559)
71. J. Tost, DNA methylation: an introduction to the biology and the disease-associated changes of a promising biomarker, Methods Mol Biol 507 (2009), 3-20.
72. R.C. Bast, Jr., B. Hennessy and G.B. Mills, The biology of ovarian cancer: new opportunities for translation, Nature Reviews Cancer 9(6) (2009), 415-428.
73. I. Ibanez de Caceres, C. Battagli, M. Esteller, J.G.Herman, E. Dulaimi, M.I. Edelson, C. Bergman, H. Ehya, B.L. Eisenberg and P. Cairns, Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients, Cancer Research 64(18) (2004), 6476-6481. (Pubitemid 39297903)
74. G. Gifford, J. Paul, P.A. Vasey, S.B. Kaye and R. Brown, The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients, Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 10(13) (2004), 4420-4426. (Pubitemid 38878884)
75. T.E. Liggett, A. Melnikov, Q. Yi, C. Replogle, W. Hu, J. Rotmensch, A. Kamat, A.K. Sood and V. Levenson, Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors, Gynecologic Oncology 120(1) (2011), 113-120.
76. A.N. Rosenthal, U. Menon and I.J. Jacobs, Screening for ovarian cancer, Clinical Obstetrics And Gynecology 49(3) (2006), 433-447. (Pubitemid 44181417)
77. R. Agarwal and S.B. Kaye, Ovarian cancer: strategies for overcoming resistance to chemotherapy, Nat Rev Cancer 3(7) (2003), 502-516. (Pubitemid 37328838)
78. C. Balch, T.H. Huang, R. Brown and K.P. Nephew, The epigenetics of ovarian cancer drug resistance and resensitization, American Journal of Obstetrics and Gynecology 191(5) (2004), 1552-1572. (Pubitemid 39491180)
79. J. Helleman, M. Smid, M.P. Jansen, M.E. van der Burg and E.M. Berns, Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture, Gynecologic Oncology 117(2) (2010), 170-176.
80. L.J. Nicholson, P.R. Smith, L. Hiller, P.W. Szlosarek, C. Kimberley, J. Sehouli, D. Koensgen, A. Mustea, P. Schmid and T. Crook, Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer, International Journal of Cancer Journal International du Cancer 125(6) (2009), 1454-1463.
81. G. Strathdee, M.J.MacKean, M. Illand and R. Brown, A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer, Oncogene 18(14) (1999), 2335-2341. (Pubitemid 29192710)
82. H.Y. Su, H.C. Lai, Y.W. Lin, C.Y. Liu, C.K. Chen, Y.C. Chou, S.P. Lin,W.C. Lin, H.Y. Lee and M.H. Yu, Epigenetic silencing of SFRP5 is related tomalignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway, International Journal of Cancer Journal International du cancer (2009).
83. O.W. Yap, G. Bhat, L. Liu and T.O. Tollefsbol, Epigenetic modifications of the Estrogen receptor beta gene in epithelial ovarian cancer cells, Anticancer Res 29(1) (2009), 139-144.
84. G. Strathdee, J.K. Vass, K.A. Oien, N. Siddiqui, J. Curto- Garcia, and R. Brown, Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy, Gynecologic Oncology 97(3) (2005), 898-903. (Pubitemid 40824663)
85. J. Song, M. Shih Ie, D.W. Chan and Z. Zhang, Suppression of annexin A11 in ovarian cancer: implications in chemoresistance, Neoplasia 11(6) (2009), 605-614, 601 p following 614.
86. P.S. Lee, V.S. Teaberry, A.E. Bland, Z. Huang, R.S.Whitaker, T. Baba, S. Fujii, A.A. Secord, A. Berchuck and S.K. Murphy, Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer, International Journal of Cancer Journal International du Cancer (2009).
87. A. Woloszynska-Read, S.R. James, P.A. Link, J. Yu, K. Odunsi and A.R. Karpf, DNAmethylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer, Cancer Immun 7 (2007), 21.
88. B. Litkouhi, J. Kwong, C.M. Lo, J.G. Smedley, 3rd, B.A. McClane, M. Aponte, Z. Gao, J.L. Sarno, J. Hinners, W.R. Welch, R.S. Berkowitz, S.C.Mok and E.I. Garner, Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin, Neoplasia 9(4) (2007), 304-314. (Pubitemid 46608297)
89. A. Gupta, A.K. Godwin, L. Vanderveer, A. Lu and J. Liu, Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma, Cancer research 63(3) (2003), 664-673. (Pubitemid 36158146)
90. E.E. Bram, M. Stark, S. Raz and Y.G. Assaraf, Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance. Neoplasia 11 (12) (2009), 1359-1370.
91. S.L. Rose, M.P. Fitzgerald, N.O. White, M.J. Hitchler, B.W. Futscher, K. De Geest and F.E. Domann, Epigenetic regulation of maspin expression in human ovarian carcinoma cells, Gynecologic Oncology 102(2) (2006), 319-324. (Pubitemid 44056261)
92. H. Honda, M.J. Pazin, T. D'Souza, H. Ji and P.J.Morin, Regulation of the CLDN3 gene in ovarian cancer cells, Cancer Biol Ther 6(11) (2007), 1733-1742. (Pubitemid 351590308)
93. Y.L. Choi, J. Kim,M.J. Kwon, J.S. Choi, T.J. Kim, D.S. Bae, S.S. Koh, Y.H. In, Y.W. Park, s.H. Kim, G. Ahn and Y.K. Shin,Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation, Histol Histopathol 22(11) (2007), 1185-1195. (Pubitemid 47470312)
94. H. Cedar and Y. Bergman, Linking DNA methylation and histone modification: patterns and paradigms, Nat Rev Genet 10(5) (2009), 295-304.
95. E.I. Campos and D. Reinberg, Histones: Annotating Chromatin, Annu Rev Genet 43 (2009), 559-599.
96. M.F. Fraga, E. Ballestar, A. Villar-Garea, M. Boix-Chornet, J. Espada, G. Schotta, T. Bonaldi, C. Haydon, S. Ropero, K. Petrie, N.G. Iyer, A. Perez-Rosado, E. Calvo, J.A. Lopez, A. Cano, M.J. Calasanz, D. Colomer, M.A. Piris, N. Ahn, A. Imhof, C. Caldas, T. Jenuwein and M. Esteller, (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer, Nat Genet 37(4) (2009), 391-400.
97. T.S. Mikkelsen, M. Ku, D.B. Jaffe, B. Issac, E. Lieberman, G. Giannoukos, P. Alvarez, W. Brockman, T.K. Kim, R.P. Koche, W. Lee, E. Mendenhall, A. O'Donovan, A. Presser, C. Russ, X. Xie, A. Meissner, M. Wernig, R. Jaenisch, C. Nusbaum, E.S. Lander and B.E. Bernstein, Genome-wide maps of chromatin state in pluripotent and lineage-committed cells, Nature 448(7153) (2007), 553-560. (Pubitemid 47206934)
98. Q. Gan, T. Yoshida, O.G. McDonald and G.K. Owens, Concise review: epigenetic mechanisms contribute to pluripotency and cell lineage determination of embryonic stem cells, Stem Cells 25(1) (2007), 2-9. (Pubitemid 46052969)
99. J.E. Ohm, K.M. McGarvey, X. Yu, L. Cheng, K.E. Schuebel, L. Cope, H.P. Mohammad, W. Chen, V.C. Daniel, W. Yu, D.M. Berman, T. Jenuwein, K. Pruitt, S.J. Sharkis, D.N. Watkins, J.G. Herman and S.B. Baylin, A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing, Nat Genet 39(2) (2007), 237-242. (Pubitemid 46184356)
100. M.R. Rountree, K.E. Bachman, J.G. Herman and S.B.Baylin, DNA methylation, chromatin inheritance, and cancer, Oncogene 20(24) (2001), 3156-3165. (Pubitemid 32553571)
101. M.G. Lee, C.Wynder, D.A. Bochar, M.A. Hakimi, N. Cooch and R. Shiekhattar, Functional interplay between histone demethylase and deacetylase enzymes,Mol Cell Biol 26(17) (2006), 6395-6402. (Pubitemid 44277880)
102. A. Sparmann and M. van Lohuizen, Polycomb silencers control cell fate, development and cancer, Nat Rev Cancer 6(11) (2006), 846-856. (Pubitemid 44629896)
103. W. Weichert, C. Denkert, A. Noske, S. Darb-Esfahani, M. Dietel, S.E. Kalloger, D.G. Huntsman and M. Kobel, Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas, Neoplasia 10(9) (2008), 1021-1027.
104. L. Zhen, L. Gui-lan, Y. Ping, H. Jin andW. Ya-li, The expression of H3K9Ac, H3K14Ac, and H4K20TriMe in epithelial ovarian tumors and the clinical significance, International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society 20(1) (2010), 82-86.
105. C. Caslini, C.D. Capo-chichi, I.H. Roland, E. Nicolas, A.T. Yeung and X.X.Xu, Histone modifications silence the GATA transcription factor genes in ovarian cancer, Oncogene 25(39) (2006), 5446-5461. (Pubitemid 44330287)
106. K.A. Strait, B. Dabbas, E.H. Hammond, C.T. Warnick, S.J. Iistrup and C.D. Ford, Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteins, Mol Cancer Ther 1(13) (2002), 1181-1190.
107. M.J. Kwon, S.S. Kim, Y.L. Choi, H.S. Jung, C. Balch, S.H. Kim, Y.S. Song, V.E. Marquez, K.P. Nephew and Y.K. Shin, Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modifications, Carcinogenesis 31(6) (2010), 974-983.
108. P.H. Abbosh, J.S. Montgomery, J.A. Starkey, M. Novotny, E.G. Zuhowski, M.J. Egorin, A.P.Moseman, A. Golas, K.M. Brannon, C. Balch, T.H. Huang and K.P. Nephew, Dominantnegative histone H3 lysine 27mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells, Cancer Research 66(11) (2006), 5582-5591. (Pubitemid 43927108)
109. H. Li, Q. Cai, A.K. Godwin and R. Zhang, Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells, Molecular Cancer Research: MCR 8(12) (2010), 1610-1618.
110. Z.Y. Rao, M.Y. Cai, G.F. Yang, L.R. He, S.J. Mai, W.F. Hua, Y.J. Liao, H.X. Deng, Y.C. Chen, X.Y. Guan, Y.X. Zeng, H.F. Kung and D. Xie, EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients, Carcinogenesis 31(9) (2010), 1576-1583.
111. C. Lu, H.D. Han, L.S. Mangala, R. Ali-Fehmi, C.S. Newton, L. Ozbun, G.N. Armaiz-Pena, W. Hu, R.L. Stone, A. Munkarah, M.K. Ravoori, M.M. Shahzad, J.W. Lee, E. Mora, R.R. Langley, A.R. Carroll, K. Matsuo, W.A. Spannuth, R. Schmandt, N.B. Jennings, B.W. Goodman, R.B. Jaffe, A.M. Nick, H.S. Kim, E.O. Guven, Y.H. Chen, L.Y. Li,M.C. Hsu, R.L. Coleman, G.A. Calin, E.B. Denkbas, J.Y. Lim, J.S. Lee, V. Kundra, M.J. Birrer, M.C. Hung, G. Lopez-Berestein and A.K. Sood, Regulation of tumor angiogenesis by EZH2, Cancer Cell 18(2) (2010), 185-197.
112. G. Yin, R. Chen, A.B. Alvero, H.H. Fu, J. Holmberg, C. Glackin, T. Rutherford and G. Mor, TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214, Oncogene 29(24) (2010), 3545-3553.
113. J.M. Friedman and P.A. Jones, MicroRNAs: critical mediators of differentiation, development and disease, Swiss Med Wkly 139(33-34) (2009), 466-472.
114. W.M. Merritt, Y.G. Lin, L.Y. Han, A.A. Kamat, W.A. Spannuth, R. Schmandt, D.Urbauer, L.A. Pennacchio, J.F. Cheng, A.M. Nick, M.T. Deavers, A. Mourad-Zeidan, H. Wang, P. Mueller, M.E. Lenburg, J.W. Gray, S. Mok, M.J. Birrer, G. Lopez-Berestein, R.L. Coleman, M. Bar-Eli and A.K. Sood, Dicer, Drosha, and outcomes in patients with ovarian cancer, N Engl J Med 359(25) (2008), 2641-2650.
115. G. Pampalakis, E.P. Diamandis, D. Katsaros and G. Sotiropoulou, Down-regulation of dicer expression in ovarian cancer tissues, Clin Biochem (2009).
116. A. Laios, S. O'Toole, R. Flavin, C.Martin, L.Kelly,M. Ring, S.P. Finn, C. Barrett, M. Loda, N. Gleeson, T. D'Arcy, E. McGuinness, O. Sheils, B. Sheppard, J O' Leary, Potential role of miR-9 and miR-223 in recurrent ovarian cancer, Mol Cancer 7 (2008), 35.
117. L. Zhang, S. Volinia, T. Bonome, G.A. Calin, J. Greshock, N. Yang, C.G. Liu, A. Giannakakis, P. Alexiou, K. Hasegawa, C.N. Johnstone, M.S. Megraw, S. Adams, H. Lassus, J. Huang, S. Kaur, S. Liang, P. Sethupathy, A. Leminen, V.A. Simossis, R. Sandaltzopoulos, Y.Naomoto, D.Katsaros, P.A. Gimotty, A. DeMichele, Q. Huang, R. Butzow, A.K. Rustgi, B.L.Weber, M.J. Birrer, A.G. Hatzigeorgiou, C.M. Croce and G. Coukos, Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer, Proc Natl Acad Sci USA 105(19) (2008), 7004-7009. (Pubitemid 351754520)
118. L. Zhang, J. Huang, N. Yang, J. Greshock, M.S. Megraw, A. Giannakakis, S. Liang, T.L. Naylor, A. Barchetti, M.R. Ward, G. Yao, A. Medina, A. O'Brien-Jenkins, D. Katsaros, A. Hatzigeorgiou, P.A. Gimotty, B.L.Weber, G. Coukos, microRNAs exhibit high frequency genomic alterations in human cancer, Proc Natl Acad Sci USA 103(24) (2006), 9136-9141. (Pubitemid 43902545)
119. D.D. Taylor and C. Gercel-Taylor, MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer, Gynecologic Oncology 110(1) (2008), 13-21. (Pubitemid 351853251)
120. C. Roth, S. Kasimir-Bauer, M. Heubner, K. Pantel and H. Schwarzenbach, Increase in circulating microRNA levels in blood of ovarian cancer patients, in: Circulating Nucleic Acids in Plasma and Serum, P.B. Gahan, ed., Proceedings of the 6th International Conference on Circulating Nucleic Acids in Plasma and Serum, Springer, New York, NY, 2011, pp. 63-71.
121. J.L. Bearfoot, D.Y. Choong, K.L. Gorringe and I.G. Campbell, Genetic analysis of cancer-implicated MicroRNA in ovarian cancer, Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 14(22) (2008), 7246-7250.
122. N. Dahiya and P.Morin,MicroRNAs in Ovarian Carcinomas, Endocr Relat Cancer (2009).
123. M.V. Iorio, R. Visone, G. Di Leva, V. Donati, F. Petrocca, P. Casalini, C. Taccioli, S. Volinia, C.G. Liu, H. Alder, G.A. Calin, S. Menard and C.M. Croce, MicroRNA signatures in human ovarian cancer, Cancer Research 67(18) (2007), 8699-8707. (Pubitemid 47437445)
124. E.J. Nam, H. Yoon, S.W. Kim, H. Kim, Y.T. Kim, J.H. Kim, J.W. Kim and S. Kim, MicroRNA expression profiles in serous ovarian carcinoma, Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 14(9) (2008), 2690-2695.
125. C.H. Lee, S. Subramanian, A.H. Beck, I. Espinosa, J. Senz, S.X. Zhu, D. Huntsman, M. van de Rijn and C.B. Gilks, MicroRNA profiling of BRCA1/2 mutation-carrying and nonmutation- carrying high-grade serous carcinomas of ovary, PloS One 4(10) (2009), e7314.
126. R. Bhattacharya, M. Nicoloso, R. Arvizo, E. Wang, A. Cortez, S. Rossi, G.A. Calin and P.Mukherjee, MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer, Cancer Research 69(23) (2009), 9090-9095.
127. S. Varambally, Q. Cao, R.S. Mani, S. Shankar, X. Wang, B. Ateeq, B. Laxman, X. Cao, X. Jing, K. Ramnarayanan, J.C. Brenner, J. Yu, J.H. Kim, B. Han, P. Tan, C. Kumar-Sinha, R.J. Lonigro, N. Palanisamy, C.A. Maher and A.M. Chinnaiyan, Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer, Science 322(5908) (2008), 1695-1699.
128. N. Yang, S. Kaur, S. Volinia, J. Greshock, H. Lassus, K. Hasegawa, S. Liang, A. Leminen, S. Deng, L. Smith, C.N. Johnstone, X.M. Chen, C.G. Liu, Q. Huang, D. Katsaros, G.A. Calin, B.L.Weber, R. Butzow, C.M. Croce, G. Coukos and
129. A. Bendoraite, E.C. Knouf, K.S. Garg, R.K. Parkin, E.M. Kroh, K.C. O'Briant, A.P. Ventura, A.K. Godwin, B.Y. Karlan, C.W. Drescher, N. Urban, B.S. Knudsen and M. Tewari, Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition, Gynecologic Oncology 116(1) (2010), 117-125.
130. X. Hu, D.M. Macdonald, P.C. Huettner, Z. Feng, I.M. El Naqa, J.K. Schwarz, D.G. Mutch, P.W. Grigsby, S.N. Powell and X. Wang, A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer, Gynecologic Oncology 114(3) (2009), 457-464.
131. R.C. Bast, Jr., M. Brewer, C. Zou, M.A. Hernandez, M. Daley, R. Ozols, K. Lu, Z. Lu, D. Badgwell, G.B. Mills, S. Skates, Z. Zhang, D. Chan, A. Lokshin and Y. Yu, Prevention and early detection of ovarian cancer: mission impossible? Recent Results Cancer Res 174 (2007), 91-100.
132. A. Cicalese, G. Bonizzi, C.E. Pasi, M. Faretta, S. Ronzoni, B. Giulini, C. Brisken, S.Minucci, P.P.Di Fiore and P.G. Pelicci, The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells, Cell 138(6) (2009), 1083-1095.
133. A. Ahluwalia, P. Yan, J.A. Hurteau, R.M. Bigsby, S.H. Jung, T.H. Huang, and K.P.Nephew, DNAmethylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization, Gynecologic Oncology 82(2) (2001), 261-268. (Pubitemid 32730601)
134. S.H. Wei, C. Balch, H.H. Paik, Y.S. Kim, R.L. Baldwin, S. Liyanarachchi, L. Li, Z.Wang, J.C.Wan, R.V. Davuluri, B.Y. Karlan, G. Gifford, R. Brown, S. Kim, T.H. Huang and K.P. Nephew, Prognostic DNAmethylation biomarkers in ovarian cancer, Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 12(9) (2006), 2788-2794.
135. S.H.Wei, C.M. Chen, G. Strathdee, J. Harnsomburana, C.R. Shyu, F. Rahmatpanah, H. Shi, S.W. Ng, P.S. Yan, K.P. Nephew, R. Brown and T.H. Huang, Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers, Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 8(7) (2002), 2246-2252. (Pubitemid 34753597)
136. A.E. Teschendorff, U. Menon, A. Gentry-Maharaj, S.J. Ramus, S.A. Gayther, S. Apostolidou, A. Jones, M. Lechner, S. Beck, I.J. Jacobs and M. Widschwendter, An epigenetic signature in peripheral blood predicts active ovarian cancer, PloS One 4(12) (2009), e8274.
137. M. Shih Ie, L. Chen, C.C. Wang, J. Gu, B. Davidson, L. Cope, R.J. Kurman, J. Xuan and T.L. Wang, Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis, American Journal of Obstetrics and Gynecology 203(6) (2010), 584, e581-e522.
138. M. Boettcher, F. Kischkel and J.D. Hoheisel, High-definition DNAmethylation profiles frombreast and ovarian carcinoma cell lines with differing doxorubicin resistance, PloS One 5(6) (2010), e11002.
139. R. Michaelson-Cohen, I. Keshet, R. Straussman, M. Hecht, H. Cedar and U. Beller, Genome-wide de novo methylation in epithelial ovarian cancer, International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society 21(2) (2011), 269-279.
140. S. Houshdaran, S. Hawley, C. Palmer, M. Campan, M.N. Olsen, A.P. Ventura, B.S. Knudsen, C.W. Drescher, N.D. Urban, P.O. Brown and P.W.Laird, DNAmethylation profiles of ovarian epithelial carcinoma tumors and cell lines, PloS One 5(2) (2010), e9359.
141. N. Matsumura, Z. Huang, S. Mori, T. Baba, S. Fujii, I. Konishi, E.S. Iversen, A. Berchuck and S.K. Murphy, Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer, Genome Res 21(1) (2011), 74-82.
142. H. Qin, M.W. Chan, S. Liyanarachchi, C. Balch, D. Potter, I.J. Souriraj, A.S. Cheng, F.J. Agosto-Perez, E.V. Nikonova, P.S. Yan, H.J. Lin, K.P. Nephew, J.H. Saltz, L.C. Showe, T.H. Huang and R.V. Davuluri, An integrative ChIP-chip and gene expression profiling to model SMAD regulatory modules, BMC Syst Biol 3 (2009), 73.
143. J.L. Chou, H.Y. Su, L.Y. Chen, Y.P. Liao, C. Hartman-Frey, Y.H. Lai, H.W. Yang, D.E. Deatherage, C.T. Kuo, Y.W. Huang, P.S. Yan, S.H. Hsiao, C.K. Tai, H.J. Lin, R.V. Davuluri, T.K. Chao, K.P. Nephew, T.H. Huang, H.C. Lai and M.W. Chan, Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer, Laboratory Investigation; a Journal of Technical Methods and Pathology 90(3) (2010), 414-425.
144. M. Li, C. Balch, J.S. Montgomery, M. Jeong, J.H. Chung, P. Yan, T.H. Huang, S. Kim and K.P. Nephew, Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer, BMC Med Genomics 2 (2009), 34.
145. S. Nam, M. Li, K. Choi, C. Balch, S. Kim and K.P. Nephew, MicroRNA and mRNA integrated analysis (MMIA): a web tool for examining biological functions of microRNA expression, Nucleic Acids Res 37(Web Server issue) (2009), W356-W362.
146. S.A. Bapat, A. Krishnan, A.D. Ghanate, A.P. Kusumbe and R.S. Kalra, Gene expression: protein interaction systems network modeling identifies transformation-associated molecules and pathways in ovarian cancer, Cancer Research 70(12) (2010), 4809-4819.
147. T.A.Yap, C.P. Carden and S.B.Kaye, Beyond chemotherapy:targeted therapies in ovarian cancer, Nat Rev Cancer 9(3) (2009), 167-181.
148. D.E. Matei and K.P. Nephew, Epigenetic therapies for chemoresensitization of epithelial ovarian cancer, Gynecologic Oncology 116(2) (2010), 195-201.
149. M.J. Hendrix, E.A. Seftor, R.E. Seftor, J. Kasemeier-Kulesa, P.M. Kulesa and L.M. Postovit, Reprogramming metastatic tumour cells with embryonic microenvironments, Nature Reviews Cancer 7(4) (2007), 246-255. (Pubitemid 46480969)
150. S.A. Bapat, V. Jin, N. Berry, C. Balch, N. Sharma, N. Kurrey, S. Zhang, F. Fang, X. Lan, M. Li, B. Kennedy, R.M. Bigsby, T.H. Huang nad K.P. Nephew, Multivalent epigenetic marks confer microenvironment-responsive epigenetic plasticity to ovarian cancer cells, Epigenetics: Official Journal of the DNA Methylation Society 5(8) (2010), 716-729.
151. N. Eckstein, K. Servan, B. Hildebrandt, A. Politz, G. von Jonquieres, S. Wolf-Kummeth, I. Napierski, A. Hamacher, M.U. Kassack, J. Budczies, M. Beier, M. Dietel, B. Royer- Pokora, C. Denkert and H.D. Royer, Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells, Cancer Research 69(7) (2009), 2996-3003.
152. L. Lu, D. Katsaros, I.A. de la Longrais, O. Sochirca and H. Yu, Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis, Cancer Research 67(21) (2007), 10117-10122. (Pubitemid 350070782)
153. X. Yang, F. Lay, H. Han and P.A. Jones, Targeting DNA methylation for epigenetic therapy, Trends Pharmacol Sci 31(11) (2010), 536-546.
154. K. Patel, J. Dickson, S. Din, K. Macleod, D. Jodrell and B. Ramsahoye, Targeting of 5-aza-2'-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme, Nucleic Acids Research 38(13) (2010), 4313-4324.
155. C.B. Yoo and P.A. Jones, Epigenetic therapy of cancer: past, present and future, Nat Rev Drug Discov 5(1) (2006), 37-50.
156. E. Jabbour, J.P. Issa, G. Garcia-Manero and H. Kantarjian, Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies, Cancer 112(11) (2008), 2341-2351.
157. N. Takai, N. Kawamata, C.S.Walsh, S. Gery, J.C. Desmond, S. Whittaker, J.W. Said, L.M. Popoviciu, P.A. Jones, I. Miyakawa and H.P. Koeffler, Discovery of epigenetically masked tumor suppressor genes in endometrial cancer, Molecular Cancer Research 3(5) (2005), 261-269. (Pubitemid 40656813)
158. M. Sasaki, M. Kaneuchi, S. Fujimoto, Y. Tanaka and R. Dahiya, Hypermethylation can selectively silence multiple promoters of steroid receptors in cancers, Mol Cell Endocrinol 202(1-2) (2003), 201-207. (Pubitemid 36593413)
159. J.L. Medina-Franco andT. Caulfield, Advances in the computational development of DNA methyltransferase inhibitors, Drug Discov Today (2011).
160. P. Siedlecki, R. Garcia Boy, T. Musch, B. Brueckner, S. Suhai, F. Lyko and P. Zielenkiewicz, Discovery of two novel, small-molecule inhibitors of DNA methylation, J Med Chem 49(2) (2006), 678-683. (Pubitemid 43157497)
161. C.B. Yoo, S. Jeong, G. Egger, G. Liang, P. Phiasivongsa, C. Tang, S. Redkar and P.A. Jones, Delivery of 5-aza-2'- deoxycytidine to cells using oligodeoxynucleotides, Cancer Research 67(13) (2007), 6400-6408. (Pubitemid 47037524)
162. L.G. Hudson, R. Zeineldin and M.S. Stack, Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression, Clinical & Experimental Metastasis 25(6) (2008), 643-655.
163. C. Balch, P. Yan, T. Craft, S. Young, D.G. Skalnik, T.H. Huang and K.P. Nephew, Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer, Mol Cancer Ther 4(10) (2005), 1505-1514. (Pubitemid 41556432)
164. Y.W. Leu, F. Rahmatpanah, H. Shi, S.H. Wei, J.C. Liu, P.S. Yan, T.H. Huang, Double RNA interference of DNMT3b and DNMT1 enhances DNA demethylation and gene reactivation, Cancer Research 63(19) (2003), 6110-6115. (Pubitemid 37255146)
165. R. Plummer, L. Vidal, M. Griffin, M. Lesley, J. de Bono, S. Coulthard, J. Sludden, L.L. Siu, E.X. Chen, A.M. Oza, G.K. Reid, A.R. McLeod, J.M. Besterman, C. Lee, I. Judson, H. Calvert and A.V. Boddy, Phase I study of MG98, an oligonucleotide antisense inhibitor of humanDNAmethyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors, Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 15(9) (2009), 3177-3183.
166. B. Brueckner, R. Garcia Boy, P. Siedlecki, T. Musch, H.C. Kliem, P. Zielenkiewicz, S Suhai, M. Wiessler and F. Lyko, Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases, Cancer Research 65(14) (2005), 6305-6311. (Pubitemid 40994416)
167. J. Datta, K. Ghoshal, W.A. Denny, S.A. Gamage, D.G. Brooke, P. Phiasivongsa, S. Redkar and S.T. Jacob, A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation, Cancer Research 69(10) (2009), 4277-4285.
168. S. Minucci and P.G. Pelicci, Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer, Nat Rev Cancer 6(1) (2006), 38-51. (Pubitemid 43054973)
169. L. Qiu, A. Burgess, D.P. Fairlie, H. Leonard, P.G. Parsons and B.G. Gabrielli, Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells, Mol Biol Cell 11(6) (2000), 2069-2083. (Pubitemid 30408065)
170. K.A. Strait, C.T.Warnick, C.D. Ford, B. Dabbas, E.H. Hammond and S.J. Ilstrup, Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad, Mol Cancer Ther 4(4) (2005), 603-611. (Pubitemid 40601842)
171. C. Choudhary, C.Kumar, F.Gnad, M.L. Nielsen, M. Rehman, T.C. Walther, J.V. Olsen and M. Mann, Lysine acetylation targets protein complexes and co-regulates major cellular functions, Science 325(5942) (2009), 834-840.
172. N. Batty, G.G. Malouf and J.P. Issa, Histone deacetylase inhibitors as anti-neoplastic agents, Cancer Lett 280(2) (2009), 192-200.
173. J.A. Plumb, P.W. Finn, R.J. Williams, M.J. Bandara, M.R. Romero, C.J.Watkins, N.B. La Thangue and R. Brown, Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101, Mol Cancer Ther 2(8) (2003), 721-728.
174. X. Qian, W.J. LaRochelle, G. Ara, F. Wu, K.D. Petersen, A. Thougaard, M. Sehested, H.S. Lichenstein and M. Jeffers, Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies, Mol Cancer Ther 5(8) (2006), 2086-2095. (Pubitemid 44336581)
175. H. Uchida, T. Maruyama, T. Nagashima, H. Asada and Y. Yoshimura, Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin, Endocrinology 146(12) (2005), 5365-5373. (Pubitemid 41653050)
176. N. Takai, J.C. Desmond, T. Kumagai, D. Gui, J.W. Said, S. Whittaker, I. Miyakawa and H.P. Koeffler, Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clinical Cancer Research: anOfficial Journal of the American Association for Cancer Research 10(3) (2004), 1141-1149. (Pubitemid 38198916)
177. N. Takai, N. Kawamata, D. Gui, J.W. Said, I. Miyakawa and H.P. Koeffler, Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis, Cancer 101(12) (2004), 2760-2770. (Pubitemid 39603184)
178. S.C. Modesitt, M. Sill, J.S. Hoffman and D.P. Bender, A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study, Gynecologic Oncology 109(2) (2008), 182-186.
179. H. Mackay, H.W. Hirte, A. Covens, K.MacAlpine, L.Wang, M.S. Tsao, J. Pan, J.A. Zwiebel andA.M.Oza, Aphase II trial of the histone deacetylase inhibitor belinostat (PXD101) in patients with platinum resistant epithelial ovarian tumors and micropapillary/borderline (LMP) ovarian tumors. A PMH phase II consortium trial, J Clin Oncol 26(15S (May 20 Supplement)) (2008), Abstract 5518.
180. L. Morey, C. Brenner, F. Fazi, R. Villa, A. Gutierrez, M. Buschbeck, C. Nervi, S. Minucci, F. Fuks and L. Di Croce, MBD3, a component of the NuRD complex, facilitates chromatin alteration and deposition of epigenetic marks, Mol Cell Biol 28(19) (2008), 5912-5923.
181. K. Terasawa, S. Sagae, M. Toyota, K. Tsukada, K. Ogi, A. Satoh, H. Mita, K. Imai, T. Tokino and R. Kudo, Epigenetic inactivation of TMS1/ASC in ovarian cancer, Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 10(6) (2004), 2000-2006. (Pubitemid 38375559)
182. H. Shi, S.H. Wei, Y.W. Leu, F. Rahmatpanah, J.C. Liu, P.S. Yan, K.P. Nephew and T.H. Huang, Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation, Cancer Research 63(9) (2003), 2164-2171. (Pubitemid 36538622)
183. S. Venturelli, S. Armeanu, A. Pathil, C.J. Hsieh, T.S. Weiss, R. Vonthein, M. Wehrmann, M. Gregor, U.M. Lauer and M. Bitzer, Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma, Cancer 109(10) (2007), 2132-2141. (Pubitemid 46744210)
184. E.E. Cameron, K.E. Bachman, S. Myohanen, J.G. Herman and S.B. Baylin, Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer, Nat Genet 21(1) (1999), 103-107. (Pubitemid 29036293)
185. V. Zuco, V. Benedetti, M. De Cesare and F. Zunino, Sensitization of ovarian carcinoma cells to the atypical retinoid ST1926 by the histone deacetylase inhibitor, RC307: enhancedDNAdamage response, International Journal of Cancer Journal International du Cancer 126(5) (2010), 1246-1255.
186. D.S. Son, A.J.Wilson, A.K. Parl and D. Khabele, The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21, Cancer Biology & Therapy 9(11) (2010), 928-935.
187. F. Braiteh, A.O. Soriano, G. Garcia-Manero, D. Hong, M.M. Johnson, P. Silva Lde, H. Yang, S. Alexander, J. Wolff and R. Kurzrock, Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers, Clinical Cancer Research: anOfficial Journal of the American Association for Cancer Research 14(19) (2008), 6296-6301.
188. C. Balch, J.S. Montgomery, H.I. Paik, S. Kim, S. Kim, T.H. Huang and K.P. Nephew, New anti-cancer strategies: epigenetic therapies and biomarkers, Front Biosci 10 (2005), 1897-1931. (Pubitemid 40532955)
189. J. Rodon, M.D. Iniesta and K. Papadopoulos, Development of PARP inhibitors in oncology, Expert Opin Investig Drugs 18(1) (2009), 31-43.
190. B.A. Teicher, Combinations of PARP, hedgehog and HDAC inhibitors with standard drugs, Curr Opin Pharmacol 10(4) (2010), 397-404.
191. J.A. Plumb, G. Strathdee, J. Sludden, S.B. Kaye and R. Brown, Reversal of drug resistance in human tumorxenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter, Cancer Research 60(21) (2000), 6039-6044.
192. M. Candelaria, D. Gallardo-Rincon, C. Arce, L. Cetina, J.L. Aguilar-Ponce, O. Arrieta, A. Gonzalez-Fierro, A. Chavez- Blanco, E. de la Cruz-Hernandez, M.F. Camargo, C. Trejo- Becerril, E. Perez-Cardenas, C. Perez-Plasencia, L. Taja- Chayeb, T. Wegman-Ostrosky, A. Revilla-Vazquez and A. Duenas-Gonzalez, A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors, Ann Oncol 18(9) (2007), 1529-1538. (Pubitemid 47365487)
193. F. Fang, C. Balch, J. Schilder, T. Breen, S. Zhang, C. Shen, L. Li, C. Kulesavage, A.J. Snyder, K.P. Nephew and D.E. Matei, A Phase I and Pharmacodynamic Study of Decitabine in Combination with Carboplatin in Patients with Recurrent, Platinum-Resistant, Epithelial Ovarian Cancer, Cancer (2009), in press.
194. R.C. Bast, R.B. Iyer, W. Hu, J. Kavanagh, R.L. Coleman, C. Levenback, A.K. Sood, J. Wolf, D.M. Gershenson, M. Markman and S. Fu, Aphase IIa study of a sequential regimen using azacitidine to reverse platinum resistance to carboplatin in patients with platinum resistant or refractory epithelial ovarian cancer, J Clin Oncol 26(15S (May 20 Supplement)) (2008), Abstract 3500.
195. E. Vire, C. Brenner, R. Deplus, L. Blanchon, M. Fraga, C. Didelot, L. Morey, A. Van Eynde, D. Bernard, J.M. Vanderwinden, M. Bollen, M. Esteller, L. Di Croce, Y. de Launoit and F. Fuks, The Polycomb group protein EZH2 directly controls DNA methylation, Nature 439(7078) (2006), 871-874. (Pubitemid 43255707)
196. Y.T. Yang, C. Balch, S.K. Kulp, M.R. Mand, K.P. Nephew and C.S. Chen, A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer, Neoplasia 11(6) (2009), 552-563; 553 p following 563.
197. K.T. Thurn, S. Thomas, A.Moore and P.N. Munster, Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer, Future Oncol 7(2) (2011), 263-283.
198. A.L. Cooper, V.L. Greenberg, P.S. Lancaster, J.R. van Nagell, Jr., S.G. Zimmer and S.C. Modesitt, In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer, Gynecologic Oncology (2006) (epub ahead of print).
199. C.S. Dietrich, 3rd, V.L. Greenberg, C.P. DeSimone, S.C. Modesitt, J.R. van Nagell, R. Craven and S.G. Zimmer, Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines, Gynecologic Oncology 116(1) (2010), 126-130.
200. J. Sonnemann, J. Gange, S. Pilz, C. Stotzer, R. Ohlinger, A. Belau, G. Lorenz and J.F. Beck, Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients, BMC Cancer 6 (2006), 183.
201. N. Takai and H. Narahara, Histone deacetylase inhibitor therapy in epithelial ovarian cancer, J Oncol (2010), 458431.
202. N. Steele, P. Finn, R. Brown and J.A. Plumb, Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo, Br J Cancer 100(5) (2009), 758-763.
203. A.J. Simpson, O.L. Caballero, A. Jungbluth, Y.T. Chen and L.J. Old. Cancer/testis antigens, gametogenesis and cancer, Nat Rev Cancer 5(8) (2005), 615-625.
204. A.R. Karpf, A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy, Epigenetics 1(3) (2006), 116-120.
205. S.J. Adair and K.T. Hogan, Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules, Cancer Immunol Immunother 58(4) (2009), 589-601.